Sun–Organon: The scope, risks, and future of India's biggest pharma deal
About this episode
The episode discusses Sun Pharma's acquisition of Organon and its implications for the pharmaceutical industry.
India's largest drugmaker, Sun Pharma, has announced the acquisition of US-based Organon in a landmark $11.75 billion all-cash deal, the biggest overseas purchase by an Indian company since Tata-Corus in 2007. The move effectively doubles Sun Pharma's size, vaulting it into the top 25 global pharmaceutical companies with combined revenues of $12.4 billion. Host Anirban Chowdhury talks to ET's pharma expert Vikas Dandekar and associate editor Arijit Barman about why this deal gives Sun Pharma an instant foothold in biosimilars, a dominant position in global women's health, and a portfolio of established brands across 150 countries. With $2.5 billion in combined pre-financing free cash flows, the company looks well-positioned to tackle Organon's inherited debt burden. See omnystudio.com/listener for privacy information.
More episodes of The Morning Brief
Explore listener stats, chart rankings, contacts and more on the The Morning Brief podcast page.